Investigating a treatment for alcoholic chronic pancreatitis
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
This study is looking at how a drug called AMPKa agonist might help people with alcoholic chronic pancreatitis by reducing the damage caused by long-term alcohol use on the pancreas and finding new ways to improve their health.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Med Br Galveston NIH-funded |
| Lab location | 1 site (Galveston, United States) |
| Project ID | NIH-10649275 on NIH RePORTER |
What this research studies
This research focuses on understanding how a specific drug, AMPKa agonist, can help reduce the harmful effects of chronic alcohol consumption on the pancreas, particularly in patients suffering from alcoholic chronic pancreatitis (ACP). The study aims to explore the metabolic mechanisms involved in ACP and how the drug can potentially restore normal function in the pancreas. By examining the impact of alcohol on pancreatic health and testing the drug's effectiveness, the research seeks to develop new therapeutic options for patients affected by this serious condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with a history of chronic alcohol use who are experiencing symptoms of alcoholic chronic pancreatitis.
Not a fit: Patients who do not have a history of alcohol use or those with pancreatitis caused by other factors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve the health and quality of life for patients suffering from alcoholic chronic pancreatitis.
How similar studies have performed: While the approach is innovative, similar studies have shown promise in targeting metabolic pathways affected by alcohol consumption, suggesting potential for success.
Where this research is happening
Galveston, United States
- University of Texas Med Br Galveston — Galveston, United States (Active)
Researchers
- Principal investigator: Kaphalia, Bhupendra S — University of Texas Med Br Galveston
- Study coordinator: Kaphalia, Bhupendra S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.